National Health (Originator Brand) Amendment Determination 2017 (No. 6) (PB 61 of 2017) (Cth)

PB 61 of 2017

National Health (Originator Brand) Amendment Determination 2017 (No. 6)

National Health Act 1953

I, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated    27   July 2017

______________________________________

LOUISE CLARKE

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2017 (No. 6).

(2)     This Determination may also be cited as PB 61 of 2017.

1. Commencement

This Determination commences on 1 August 2017.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 25A)

insert:

25B Bosentan Tracleer

[2]   Schedule 1 (after table item 41)

insert:

41A Chorionic gonadotrophin Pregnyl

[3]   Schedule 1 (after table item 166)

insert:

166A Nortriptyline Allergron

[4]   Schedule 1 (after table item 191)

insert:

191A Pregabalin Lyrica

[5]   Schedule 1 (after table item 224)

insert:

224A	Tenofovir	Viread
224B	Tenofovir with emtricitabine	Truvada

[6]   Schedule 1 (after table item 239)

insert:

239A Valganciclovir Valcyte